Sign In
Buy NBIX
$167.35
+2.24 (+1.36%)
At Close: Jun 04, 2026
Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
02:35am, Thursday, 09'th May 2024
Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
08:30am, Wednesday, 08'th May 2024
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, p
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
04:15pm, Tuesday, 07'th May 2024
SAN DIEGO , May 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m.
CAHtalyst™ Pediatric and CAHtalyst™ Adult Baseline Characteristics Data in Congenital Adrenal Hyperplasia Phase 2 (CHAMPAIN) Clinical Study Data for Modified-Release Hydrocortisone (Chronocort®/E
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
08:30am, Monday, 06'th May 2024
Approximately 600,000 people in the United States live with tardive dyskinesia (TD), and about 65% have not yet been diagnosed1-3 The diagnosis rate can be improved by increasing routine TD screenings
Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam
08:00am, Saturday, 04'th May 2024
Nvidia stock along with four other leading stocks are in or near buy areas as the market rally appears to be picking up steam.
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
01:15pm, Friday, 03'rd May 2024
CAHtalyst™ Pediatric Study Baseline Characteristics Data Highlight Need for Novel Treatments in Children and Adolescents with Congenital Adrenal Hyperplasia (CAH) CAHtalog™ Registry Data of Glucoc
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
10:35am, Wednesday, 01'st May 2024
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Stre
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
09:15am, Wednesday, 01'st May 2024
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $1.04 per share. This compares to loss of $0.79 per share a year ago.
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
07:00am, Wednesday, 01'st May 2024
INGREZZA® (valbenazine) First Quarter Net Product Sales of $506 Million Representing 23% Year-Over-Year Growth INGREZZA® SPRINKLE (valbenazine) Capsules Approved by the U.S. FDA Crinecerfont New Dru
FDA approves Neurocrine Biosciences' Huntington's disease drug
05:32pm, Tuesday, 30'th Apr 2024
The U.S. Food and Drug Administration (FDA) has approved granule formulation of Neurocrine Biosciences' drug to treat movement disorders associated with Huntington's disease, the company said on Tuesd
Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
05:12pm, Tuesday, 30'th Apr 2024
SAN DIEGO , April 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE (valbenazine) capsules, a
Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics
10:20am, Tuesday, 30'th Apr 2024
Beyond analysts' top -and-bottom-line estimates for Neurocrine (NBIX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quar
Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
06:28pm, Thursday, 25'th Apr 2024
Neurocrine Biosciences, Inc. achieved positive results achieved from phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with Major Depressive Disorder. NBI-1065845 may offer some ad
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
11:07am, Wednesday, 24'th Apr 2024
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
